1Simes J, Furberg CD, Braunwald E, Davis BR, Ford I, Tonkin A, et al.Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels.The Prospective Pravastatin Pooling project.Eur Heart J, 2002, 23 (3):207-215
2Scandinavian Simvastatin Survival Study Group.Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease:the Scandinavian Simvastatin Survival Study (4S).Lancet, 1994, 344:1 383-389
3Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al.Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels:results of AFCAPS/TexCAPS.Air Force/Texas Coronary Atherosclerosis Prevention Study.J Am Med Assoc, 1998, 279 (20):1 615-622
4Plutzky J, Ridker PM.Statins for Stroke:The Second Story? Circulation, 2002, 103 (3):348-350
5Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, et al.Effect of pravastatin on outcomes after cardiac transplantation.N Engl J Med, 1995, 333 (10):621-627
6Wenke K, Meiser B, Thiery J, Nagel D, Scheidt WV, Steinbeck G, et al.Simvastatin reduces graft vessel disease and mortality after heart transplantation.Circulation, 1997, 96 (5):1 398-402
7Strandberg TE, Vanhanen H, Tikkanen MJ.Effect of statins on C-reactive protein with coronary artery disease.Lancet, 1999, 353(9147):118-119
8Rider PM, Rifai N, Pfeffer M, Sacks F, Braunwald E.For the cholesterol and recurrent event (CARE) investigators.Long-term effects of pravastatin on plasma concentration of C-reactive protein.Circulation, 1999, 100 (3):230-235
10Albert MA, Danielson E, Rifai N, Ridker PM.Effect of statin therapy on C-reactive protein levels - The Pravastatin Inflammation / CRP Evaluation (PRINCE):A randomize trial and cohort study.J Am Med Assoc, 2001, 286 (1):64-70
3Schonbeck U, Sukhova GK, Shimizu K, et al. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Nail Acad Sci USA, 2000, 97: 7458-7463.
4Lutgens E, Cleutjens KBJM, Heeneman S, et al. Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc Nail Aced Sci. USA, 2000, 97: 7464-7469.
5Kai H,Ikeda H, Yasukawa H, et al. Perpherial blood levels of matrix metalloproteinase-2 and 9 are evelated In patients with acute coronary sndrome. J Am Coll Cardiol , 1998,32:368-372.
6Taku T, Toshio H, Hatsuyo K, et al. Cerivastatin, a HMG-CoA Reductase Inhibitor, Improves Endothelial Function In Elderly Diabetics winthin 3 days. Circulation, 2001,104:376-379.
7Ross R. Atherosclerosis-An inflammatory disease. N Eng J Med, 1999,340: 115-126.
8Goran K Hansson. Immune Mechanism In Atherosclerosis Arteroscler Thromb Vasc Biol . 2001,21:1876-1890.
9Koefig W. Inflammation and coronary heart disease:an overview Cardiol Rev, 2001,9:31-35.
10Mach F, Schonbeck U, Bonnefoy JY, et al. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation, 1997,96:396-399.
